Treatment shortening and relapse control in drug-susceptible pulmonary tuberculosis: a network meta-analysis of randomized trials
Abstract
Drug-susceptible pulmonary tuberculosis (DS-PTB) is conventionally treated with a 6-month multidrug regimen, but prolonged treatment may compromise adherence, prompting efforts to develop shorter and effective therapeutic strategies. However, the comparative long-term effectiveness of alternative regimens, particularly their ability to prevent relapse, remains uncertain. We systematically searched multiple databases from inception through August 31, 2025, for randomized controlled trials enrolling adolescents and adults with DS-PTB. Regimens were classified according to treatment duration and architecture, including standard 6-month therapy, rifamycin-intensified strategies, structurally modified 6-month regimens, 4-month treatment-shortening approaches, and intended 8-week multidrug regimens. A random-effects pairwise meta-analysis and a fixed-effect consistency network meta-analysis (NMA) compared treatment success, relapse/recurrence-related outcomes, and mortality. Eight randomized controlled trials involving 10,244 participants were included. Six source trials involving 8,457 randomized participants contributed to the quantitative synthesis and informed a 14-node NMA; outcome data from 6,752 participants contributed to 12 shortened-regimen-versus-standard comparisons in the pairwise meta-analysis. Two trials involving 1,787 participants were summarized narratively because their thrice-weekly control regimens were not considered exchangeable with the daily reference…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 10,244 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.